Bank of New York Mellon
ZNTL icon

Bank of New York Mellon’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bank of New York Mellon’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$592K Buy
+122,068
New +$487K ﹤0.01% 3664
2025
Q2 		– Sell
-156,115
Closed -$248K – 4283
2025
Q1 		$248K Sell
156,115
-6,820
-4% -$14.7K ﹤0.01% 3783
2024
Q4 		$494K Sell
162,935
-10,375
-6% -$34K ﹤0.01% 3538
2024
Q3 		$638K Sell
173,310
-160,409
-48% -$583K ﹤0.01% 3375
2024
Q2 		$1.36M Buy
333,719
+43,839
+15% +$490K ﹤0.01% 3013
2024
Q1 		$4.57M Sell
289,880
-256
-0.1% -$3.52K ﹤0.01% 2368
2023
Q4 		$4.4M Buy
290,136
+48,027
+20% +$701K ﹤0.01% 2437
2023
Q3 		$4.86M Buy
242,109
+77,572
+47% +$1.97M ﹤0.01% 2331
2023
Q2 		$4.64M Buy
164,537
+8,985
+6% +$216K ﹤0.01% 2366
2023
Q1 		$2.68M Sell
155,552
-2,633
-2% -$53.3K ﹤0.01% 2627
2022
Q4 		$3.19M Buy
158,185
+5,377
+4% +$116K ﹤0.01% 2591
2022
Q3 		$3.31M Buy
152,808
+34,429
+29% +$942K ﹤0.01% 2526
2022
Q2 		$3.33M Sell
118,379
-25,224
-18% -$668K ﹤0.01% 2544
2022
Q1 		$6.63M Sell
143,603
-25
-0% -$1.35K ﹤0.01% 2278
2021
Q4 		$12.1M Buy
143,628
+5,001
+4% +$387K ﹤0.01% 2000
2021
Q3 		$9.24M Buy
138,627
+43,779
+46% +$2.53M ﹤0.01% 2167
2021
Q2 		$5.05M Buy
94,848
+5,047
+6% +$270K ﹤0.01% 2478
2021
Q1 		$3.9M Sell
89,801
-6,821
-7% -$294K ﹤0.01% 2564
2020
Q4 		$5.02M Buy
96,622
+63,303
+190% +$2.86M ﹤0.01% 2351
2020
Q3 		$1.09M Buy
33,319
+2,157
+7% +$75.5K ﹤0.01% 3079
2020
Q2 		$1.5M Buy
+31,162
New +$1.2M ﹤0.01% 2857

Other funds holding ZNTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Bank of New York Mellon's ZNTL Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 122,068 shares worth $592K. The stake represents ﹤0.01% of the portfolio and ranks #3664 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in ZNTL as recently as Q1 2025.

Bank of New York Mellon first reported a position in ZNTL in Q2 2020 and has held it in 21 quarters since. The position peaked at $12.1M in Q4 2021. 48 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Bank of New York Mellon held 122,068 shares of Zentalis Pharmaceuticals worth $592K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Bank of New York Mellon position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3664 holding.
  • Bank of New York Mellon first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • Bank of New York Mellon's Zentalis Pharmaceuticals position peaked at $12.1M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.